One hundred and twenty-three anaerobic isolates from Cape Town, South Africa, were tested in vitro against cefoxitin, chloramphenicol, metronidazole, co-amoxiclav, benzylpenicillin and clindamycin. Forty-five Gram-positive organisms were tested against RP59500 (a streptogramin). Resistance in the Gram-positive isolates was as follows: of the Clostridium perfringens isolates, 4% were resistant to benzylpenicillin and 4% to clindamycin; of the Peptostreptococcus anaerobius isolates, 10% were resistant to benzylpenicillin, 10% to cefoxitin and 10% to metronidazole; of the isolates of Peptostreptococcus spp., 12% were resistant to benzylpenicillin, 6% to metronidazole, 6% to chloramphenicol and 12% to RP59500. Of the Gram-negative organisms, those in the Bacteroides fragilis group were resistant to benzylpenicillin (83%), cefoxitin (5%), clindamycin (5%) and co-amoxiclav (2%). One clindamycin-resistant B. fragilis isolate carried a plasmid homologous to the ermF erythromycin resistance determinant.
Introduction
Anaerobic bacteria are frequently isolated from soft tissue infections as mixed populations of Gram-positive and -negative organisms. It is, therefore, important that the antibiotics used in treating these infections be evaluated for efficacy against a broad spectrum of organisms, and that, within a particular hospital environment, the bacterial population be monitored for increases in resistance to the drugs used. Increasing resistance to the antibiotics used for treating anaerobic infections is being observed worldwide, but the rate at which this occurs differs between various hospitals and countries. 1 This work reports a survey of the antibiotic susceptibility of anaerobic clinical isolates from Groote Schuur Hospital, Cape Town, South Africa. No previous study of this kind had been conducted at this hospital, where the drugs of choice in treating anaerobic infections are co-amoxiclav and metronidazole. A range of antimicrobial agents was tested, including the new injectable streptogramin antibiotic, RP59500 (Rhône-Poulenc Rorer), which is effective against Gram-positive aerobic bacteria. 2 Linked resistance to macrolide-lincosamide-streptogramin B (MLS) antibiotics often occurs as a result of the presence of plasmid-borne erm genes. 3 In this study, clindamycin-resistant Bacteroides fragilis isolates were tested for linked MLS resistance to erythromycin, and examined for the presence of plasmids showing homology to the ermF resistance determinant. 4 
Materials and methods

Bacterial strains and antibiotics
Consecutive clinical isolates (123) were collected from patients at Groote Schuur Hospital, South Africa in 1995-6. All the isolates were tested in pure culture for obligate anaerobic growth. Clostridium spp. were identified using the Gram stain, the presence of spores, and the reverse CAMP test. Peptostreptococcus spp. were classified by Gram stain, morphology and sensitivity to sodium polyanethole sulphonate.
Gram-negative organisms were characterized by means of cell morphology, and MAST ID MID8 identification mast rings (Mast Diagnostics, Merseyside UK). Clostridium perfringens ATCC 13124 and B. fragilis ATCC 25285 were used as control organisms for the MIC determinations. B. fragilis V479-1 (pBF4) 4 was the positive control for ermF investigations. Anaerobic isolates were grown on Wilkins-Chalgrin agar or supplemented brain heart infusion agar at 37°C in an anaerobic growth chamber 5 (Forma Scientific, Marietta, OH, USA). Erythromycin (10 mg/L) was added to the medium for maintenance of erythromycin-resistant B. fragilis strains. Escherichia coli JM109 6 carrying the ermF gene on plasmid pVAL-1 7 was grown on YT agar 6 (10 mg/L erythromycin).
MIC determinations
The strains were tested in vitro on Wilkins-Chalgrin agar against benzylpenicillin, cefoxitin, metronidazole, chloramphenicol, clindamycin, co-amoxiclav and RP59500, using the National Committee for Clinical Laboratory Standards (NCCLS) agar dilution technique. 8 The amoxycillin:clavulanic acid ratio in co-amoxiclav was 8:4.
Plasmid analysis
Total B. fragilis DNA (chromosomal DNA and, where present, plasmid DNA) was isolated 5 and the undigested DNA separated by agarose gel (0.8%) electrophoresis, with visualization by ethidium bromide staining and UV illumination (254 nm).
Southern hybridization
Plasmid pVAL-1 was isolated 6 and a DNA probe was made from the internal BstXI-HindIII (0.31 kb) fragment of the ermF gene from plasmid pBF4. 7 Labelling was by random-primed digoxigenin incorporation (Boehringer Mannheim, Germany) according to the manufacturer's instructions, with hybridization at 60°C and visualization by chemiluminescent detection on X-ray film.
Results
Antibiotic susceptibility
The activities of the antibiotics against the different microorganisms (Table) are expressed as the range of MICs of the isolates, the MIC inhibiting 50% (MIC 50 ) or 90% (MIC 90 ) of the organisms, and modal MIC (the MIC to which most were susceptible). The sensitivity or resistance of the isolates was determined using the NCCLS breakpoints of benzylpenicillin (4 mg/L), cefoxitin (32 mg/L), metronidazole (16 mg/L), chloramphenicol (16 mg/L), clindamycin (4 mg/L) and co-amoxiclav (8:4 mg/L). The provisional breakpoint for RP59500 was 4 mg/L (manufacturer's instructions). Of the Grampositive organisms tested, 4% of the Clostridium perfringens (26 strains) were resistant to benzylpenicillin and clindamycin, but all were sensitive to the other antibiotics. The Clostridium spp. (five strains) were sensitive to all antibiotics tested. Of the 20 strains of Peptostreptococcus anaerobius, 10% were resistant to benzylpenicillin, cefoxitin and metronidazole. Of the other Peptostreptococcus spp. (17 isolates), 12% showed resistance to benzylpenicillin, and 6% to metronidazole and clindamycin. Of the eight Peptostreptococcus spp. tested against RP 59500, only one was resistant, but all eight were sensitive to chloramphenicol and co-amoxiclav. For the Gram-negative isolates, 83% of the 44 B. fragilis strains were resistant to benzylpenicillin, while 5% were resistant to cefoxitin and clindamycin, and 2% to coamoxiclav. They were sensitive to metronidazole and chloramphenicol. Of the other Gram-negative organisms tested (11 strains, including four Prevotella spp.), 45% were resistant to benzylpenicillin, but they were sensitive to the remaining antibiotics tested.
Molecular analysis
One B. fragilis isolate (Bf3) was resistant to both clindamycin (MIC > 16 mg/L) and erythromycin (MIC 256 mg/L) and contained plasmid DNA. The isolate was sensitive to RP59500, showing that it overcomes the linked MLS resistance phenotype. The ermF probe hybridized strongly to B. fragilis Bf3 DNA as well as to DNA from the control strain, B. fragilis V479-1 (pBF4) (Figure, 3 and 1, respectively). There was no hybridization to DNA from the erythromycin-sensitive B. fragilis ATCC 25285 control strain (lane 2). The ermF determinant is, therefore, present on a large plasmid in B. fragilis Bf3, or integrated into the chromosome. B. fragilis Bf3 also contained plasmid species which did not hybridize to the ermF probe.
Discussion
This study shows that, of the Gram-positive isolates, C. perfringens and the other Clostridium spp. remain most susceptible to metronidazole and co-amoxiclav. Resistance to metronidazole was, however, evident within the Peptostreptococcus group. This result is similar to the 247 findings of a 1992 study done in Johannesburg, South Africa. 9 The new injectable streptogramin antibiotic, RP59500, was 100% effective against all C. perfringens, Clostridium spp. and P. anaerobius, with only one of the eight Peptostreptococcus spp. tested being resistant. It is, therefore, a potentially useful antibiotic against Grampositive anaerobic organisms.
The Gram-negative isolates tested showed susceptibility patterns similar to those reported in a review of international surveys. 1 Resistance to benzylpenicillin ranged from 83% in the B. fragilis group to 45% in the other Gram-negative organisms. Addition of clavulanic acid, a -lactamase inhibitor, to amoxycillin, reversed this resistance, indicating that the drug resistance mechanism may lie in the production of -lactamase by the bacteria. All Gram-negative isolates were susceptible to metronidazole and chloramphenicol. Lack of chloramphenicol resistance may reflect the infrequent clinical use of this drug. It is clear that metronidazole still remains a highly effective drug for the treatment of Bacteroides spp. infections at Groote Schuur Hospital.
The B. fragilis Bf3 isolate, with linked chloramphenicol and erythromycin resistance, carried a plasmid with homology to the ermF resistance determinant. The presence of this gene in a relatively small sample of isolates is significant. The MLS resistance genes of Bacteroides spp. are plasmid-borne, highly homologous to each other (>95%), lie within a transposon or conjugative element, and are sometimes integrated into the chromosome. The transfer of plasmids carrying these genes can be mediated by other plasmids, or they may be selftransmissible. We have demonstrated that the clindamycin-and erythromycin-resistant B. fragilis Bf3 isolate contains a gene with homology to ermF. This gene is present either on a plasmid or integrated into the chromosome. In addition, the isolate contains at least one other plasmid species with no homology to ermF. Hence there is a possibility of future spread of this resistance phenotype. Confirmation of this risk would require an analysis of the transmissibility of the plasmids.
Our study provides baseline values for antibiotic susceptibility patterns of anaerobic isolates from patients at Groote Schuur Hospital. The organisms were sensitive to metronidazole and co-amoxiclav, the antibiotics currently used in treatment regimens. These results will be re-evaluated every 3 years as part of an ongoing surveillance of possible drug-resistance development.
